18.207.132.226
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Industry News

Allergan submits new drug application for investigational treatment of presbyopia

Posted on February 25, 2021

Allergan submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia, according to a company press release.

The application was based on data from 2 phase 3 trials involving 750 patients randomized to receive AGN-190584 or placebo. AGN-190584 met the primary endpoint reaching statistical significance in improvement in near vision in mesopic conditions without a loss of distance vision versus the vehicle in both studies. No treatment emergent serious adverse events were observed, and the most common treatment emergent non-serious adverse events were headache and conjunctival hyperemia.

“Presbyopia is a significant source of frustration for most adults over age 40 who find current treatments inconvenient or invasive,” said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie in the press release. “If approved, AGN-190584 is expected to be the first eye drop to treat presbyopia, providing a novel option to those affected in the U.S.”

Read the full press release here.

-Advertisement-
Related Articles
Newly formed Ophthalmology Foundation will improve global eye care through education
Mar 17, 2021
Iridex enters into strategic collaboration with Topcon Corporation
Mar 02, 2021
Medical technology company Heru, Inc completes FDA registration following a $2.7M seed round
Dec 22, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-